GlobeNewswire Inc | May 5, 2021 08:00AM EDT

May 05, 2021

SAN FRANCISCO, May 05, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that Companys Management will provide a corporate update and participate in one-on-one investor meetings at the BofA Securities 2021 Health Care Conference on Thursday, May 13, 2021 at 1:15 PM ET and the RBC Capital Markets 2021 Global Healthcare Conference on Wednesday, May 19, 2021 at 9:45 AM ET.

The live and archived webcast of the presentation will be accessible in the investor section of89bios website.

About 89bio 89bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. The companys lead product candidate, BIO89-100, is a specifically engineered glycoPEGylated analog of FGF21. BIO89-100 is being developed for the treatment of nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG). 89bio is headquartered in San Francisco with operations in Herzliya, Israel.

Investor Contact:Ryan MartinsChief Financial Officerinvestors@89bio.com

Media Contact:Peter Duckler773-343-3069pduckler@w2ogroup.com